Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.
BACKGROUND
Plerixafor (Mozobil, AMD3100) with granulocyte-colony stimulating factor (G-CSF) mobilizes more CD34+ cells/kg compared to G-CSF alone. Given that plerixafor enhances mobilization of multiple white blood cell lineages, we determined if more storage space is required for products collected from patients mobilized with plerixafor.


METHODS
A review of the medical records of 15 patients mobilized with chemotherapy and G-CSF (control) and 14 patients mobilized with plerixafor plus G-CSF (plerixafor) was performed. Data on demographics, baseline characteristics, CD34+ cells/kg, total nucleated cells, total mononuclear cells, total apheresis sessions, and total bags for storage were collected. Mean values were determined and compared using Student's t-test.


RESULTS
We found that the proportion of CD34+ cells among total nucleated cells was less in the plerixafor group compared to the control group (P = 0.0427). More nucleated cells (10.7 x 10(10) vs. 7.1 x 10(10), P =0.0452) and mononuclear cells (9.7 x 10(10) vs. 5.9 x 10(10), P = 0.0059) were mobilized with plerixafor plus G-CSF. However, there was no significant difference in CD34+ cells/kg, total CD34+ cells or the proportion of mononuclear cells among total nucleated cells between the two groups. More storage bags were required for the plerixafor group compared to the control group (15 vs. 9, P = 0.0299).


CONCLUSIONS
Mobilization with plerixafor plus G-CSF resulted in a smaller proportion of CD34+ cells collected and a greater number of storage bags. An increase in the number of bags required for stem cell storage may be logistically problematic and will also lead to increased costs for storage of stem cells.
Tanhehco
Yvette C
YC
Department of Pathology, Division of Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Adamski
Jill
J
Sell
Mary
M
Cunningham
Kathleen
K
Eisenmann
Christa
C
Magee
Deborah
D
Stadtmauer
Edward A
EA
O'Doherty
Una
U
D018952:Antigens, CD34; D001596:Benzylamines; D001781:Blood Component Removal / Q000379:methods; D001793:Blood Preservation / Q000191:economics*; D000080027:Cyclams; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006571:Heterocyclic Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007962:Leukocytes / Q000166:cytology* / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D012189:Retrospective Studies
D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor
Bone Marrow Transplant. 2007 Sep;40(5):437-41
17618321
Bone Marrow Transplant. 2009 Jun;43(12):909-17
19182831
J Clin Oncol. 2000 Mar;18(6):1360-77
10715309
Bone Marrow Transplant. 2008 Feb;41(4):331-8
17994119
Bone Marrow Transplant. 2004 May;33(9):907-12
15034543
Blood. 2009 Jun 4;113(23):5720-6
19363221
Blood. 2009 Sep 17;114(12):2530-41
19602709
Blood. 2003 Oct 15;102(8):2728-30
12855591
Leuk Lymphoma. 2008 Apr;49(4):769-78
18398746
J Clin Oncol. 2009 Oct 1;27(28):4767-73
19720922
Blood. 1994 May 1;83(9):2731-6
7513212
Bone Marrow Transplant. 2010 Jan;45(1):39-47
19483760
Transfusion. 2005 Mar;45(3):295-300
15752146
Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56
19167685
J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1253-62
15385732
Blood. 2005 Sep 1;106(5):1867-74
15890685
Eur J Cancer. 2000 Dec;36(18):2360-7
11094310
Blood. 1995 Nov 15;86(10):3961-9
7579367
Hematology. 1999;4(3):195-209
11399564
Leukemia. 2009 Oct;23(10):1904-12
19554029
Cytotherapy. 2009;11(8):992-1001
19929463